Cellectar Biosciences has partnered with Meaningful Insights-BioTech Analytics (MiBA), a data subsidiary of American Oncology Network (AON), the organization announced today.

According to a release, the partnership will look to advance the treatment of Waldenstrom’s Macroglobulinemia (WM) in the community setting.

“We are extremely pleased to be partnering with AON and MiBA to support our collective goal to enrich the WM treatment paradigm for patients and providers,” Cellectar CEO James Caruso said in a statement. “This collaboration will provide additional insight to patients’ and health care providers’ needs across the WM treatment landscape, and the learnings will be incorporated into the launch strategy for iopofosine I 131.

Financial details of the agreement were not disclosed.